The pan-ERBB inhibitor, afatinib, is a second-generation TKI which also demonstrated longer PFS in metastatic EGFR-mutated lung adenocarcinoma compared to standard chemotherapy [20,21,22]. This evidence concerns the gene EGFR and lung adenocarcinoma.